CS248712B2 - Production method of 6 alfa-methylcorticoids - Google Patents
Production method of 6 alfa-methylcorticoids Download PDFInfo
- Publication number
- CS248712B2 CS248712B2 CS838675A CS867583A CS248712B2 CS 248712 B2 CS248712 B2 CS 248712B2 CS 838675 A CS838675 A CS 838675A CS 867583 A CS867583 A CS 867583A CS 248712 B2 CS248712 B2 CS 248712B2
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- methylcorticoids
- acyloxy
- carbon atoms
- formula
- alfa
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title description 3
- 125000004423 acyloxy group Chemical group 0.000 claims abstract description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims description 5
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 3
- -1 isobutyryl Chemical group 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 241000269908 Platichthys flesus Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000028004 allergic respiratory disease Diseases 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Detergent Compositions (AREA)
- Seasonings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Manufacture Of Tobacco Products (AREA)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS8410075A CS248729B2 (cs) | 1982-11-22 | 1984-12-20 | Způsob výroby derivátů 6a-niethylkortikoidu |
| CS8410074A CS248728B2 (cs) | 1982-11-22 | 1984-12-20 | Způsob výroby derivátů βα-methylkortikoidu |
| CS8410073A CS248727B2 (cs) | 1982-11-22 | 1984-12-20 | Způsob výroby derivátů Ba-methylkortikoidu |
| CS8410076A CS248730B2 (cs) | 1982-11-22 | 1984-12-20 | Způsob výroby derivátů Ba-methylkortikoidu |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19823243482 DE3243482A1 (de) | 1982-11-22 | 1982-11-22 | Neue 6(alpha)-methylkortikoide, ihre herstellung und verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CS248712B2 true CS248712B2 (en) | 1987-02-12 |
Family
ID=6178924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS838675A CS248712B2 (en) | 1982-11-22 | 1983-11-22 | Production method of 6 alfa-methylcorticoids |
Country Status (22)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60161914A (ja) * | 1984-02-02 | 1985-08-23 | Green Cross Corp:The | ステロイド脂肪酸エステル含有直腸投与製剤 |
| JPS61274795A (ja) * | 1985-05-30 | 1986-12-04 | Toshiba Corp | 曝気槽の溶存酸素濃度制御装置 |
| US4968822A (en) * | 1987-12-11 | 1990-11-06 | Taisho Pharmaceutical Co., Ltd. | 21-alkoxysteroid compounds |
| JPH05501115A (ja) * | 1990-03-27 | 1993-03-04 | シェリング・コーポレーション | ９α―ヒドロキシ ステロイドの脱水法 |
| DE4333920A1 (de) * | 1993-10-05 | 1995-04-13 | Hoechst Ag | Corticoid-17,21-dicarbonsäureester sowie Corticosteroid-17-carbonsäureester-21-kohlensäureester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
| ITMI20011762A1 (it) | 2001-08-10 | 2003-02-10 | Cosmo Spa | Esteri di 17alfa,21-diidrossipregnene, loro uso come agenti anti-androgenetici e procedimenti per la loro preparazione |
| ITMI20071616A1 (it) | 2007-08-03 | 2009-02-04 | Cosmo Spa | Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati. |
| JP5780521B2 (ja) * | 2008-05-28 | 2015-09-16 | リベラジェン・バイオファーマ・インコーポレイテッドＲｅｖｅｒａＧｅｎ ＢｉｏＰｈａｒｍａ，Ｉｎｃ． | 疾患を治療するための、ＮＦ−κＢの非ホルモン性ステロイド調節因子 |
| EP2556083A4 (en) | 2010-04-05 | 2013-12-04 | Validus Biopharma Inc | NONHORMONAL STEROID MODULATORS OF NF-KAPPA-B FOR DISEASE TREATMENT |
| EP3108879A1 (en) | 2015-06-25 | 2016-12-28 | Cassiopea S.p.A. | High concentration formulation |
| WO2017004205A1 (en) | 2015-06-29 | 2017-01-05 | Reveragen Biopharma, Inc. | NON-HORMONAL STEROID MODULATORS OF NF-κB FOR TREATMENT OF DISEASE |
| US11382922B2 (en) | 2019-03-07 | 2022-07-12 | Reveragen Biopharma, Inc. | Aqueous oral pharmaceutical suspension compositions |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3053832A (en) * | 1957-04-29 | 1962-09-11 | Schering Corp | Alkylated cortical steroids |
| GB921533A (en) * | 1958-07-12 | 1963-03-20 | Syntex Sa | Cyclopentanophenanthrene derivatives and process for the production thereof |
| GB1047518A (en) * | 1963-06-11 | 1966-11-02 | Glaxo Lab Ltd | 17ª-monoesters of 11,17,21-trihydroxy steroid compounds |
| DE2645104C2 (de) * | 1976-10-04 | 1986-04-24 | Schering AG, 1000 Berlin und 4709 Bergkamen | 11β-Hydroxy-1,4,8-pregnatrien-3,20-dion-Derivate und Verfahren zu ihrer Herstellung |
| US4243586A (en) * | 1980-01-18 | 1981-01-06 | E. R. Squibb & Sons, Inc. | Steroidal-17-spiro-dihydrofuranones |
| US4336200A (en) * | 1980-01-31 | 1982-06-22 | The Upjohn Company | 17α-Acyloxy-5β-corticoids |
| US4318853A (en) * | 1980-01-31 | 1982-03-09 | The Upjohn Company | 9β,11β-Epoxy-5β-corticoids |
| ATE12237T1 (de) * | 1980-12-23 | 1985-04-15 | Schering Ag | Neue 6-alpha-methylhydrocortison-derivate, ihre herstellung und verwendung. |
-
1982
- 1982-11-22 DE DE19823243482 patent/DE3243482A1/de not_active Withdrawn
-
1983
- 1983-09-20 AT AT83109308T patent/ATE28651T1/de not_active IP Right Cessation
- 1983-09-20 DE DE8383109308T patent/DE3372776D1/de not_active Expired
- 1983-09-20 EP EP83109308A patent/EP0110041B1/de not_active Expired
- 1983-09-28 PT PT77408A patent/PT77408B/pt not_active IP Right Cessation
- 1983-10-13 ES ES526446A patent/ES8405421A1/es not_active Expired
- 1983-10-17 GB GB08327736A patent/GB2130587A/en not_active Withdrawn
- 1983-11-04 AU AU20989/83A patent/AU2098983A/en not_active Abandoned
- 1983-11-08 IL IL70160A patent/IL70160A/xx not_active IP Right Cessation
- 1983-11-18 DD DD83256872A patent/DD219200A5/de not_active IP Right Cessation
- 1983-11-21 PL PL1983250735A patent/PL141686B1/pl unknown
- 1983-11-21 PL PL25073483A patent/PL250734A1/xx unknown
- 1983-11-21 HU HU834000A patent/HU190746B/hu not_active IP Right Cessation
- 1983-11-21 RO RO83112614A patent/RO89343A/ro unknown
- 1983-11-21 CA CA000441605A patent/CA1303607C/en not_active Expired - Lifetime
- 1983-11-21 RO RO122112A patent/RO93593B/ro unknown
- 1983-11-21 PL PL1983244685A patent/PL138796B1/pl unknown
- 1983-11-21 NO NO834265A patent/NO157454C/no unknown
- 1983-11-21 GR GR73030A patent/GR79725B/el unknown
- 1983-11-21 IE IE2708/83A patent/IE56281B1/en not_active IP Right Cessation
- 1983-11-22 ZA ZA838720A patent/ZA838720B/xx unknown
- 1983-11-22 BG BG063156A patent/BG42677A3/xx unknown
- 1983-11-22 CS CS838675A patent/CS248712B2/cs unknown
- 1983-11-22 US US06/554,418 patent/US4645763A/en not_active Expired - Lifetime
- 1983-11-22 BG BG070923A patent/BG43867A3/xx unknown
- 1983-11-22 JP JP58218852A patent/JPS59106500A/ja active Granted
- 1983-11-22 DK DK533783A patent/DK159686C/da active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2711493C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| Rodrı́guez et al. | Oleanolic acid promotes healing of acetic acid-induced chronic gastric lesions in rats | |
| RU2361601C2 (ru) | Композиция для лечения атопических дерматитов, аллергических состояний кожи и угрей | |
| CS248712B2 (en) | Production method of 6 alfa-methylcorticoids | |
| KR20120047240A (ko) | 주사 또는 홍안 관련 피부 질환의 치료를 위한, 베르베린 또는 그의 유사체를 함유하는 조성물 | |
| BR0014563A (pt) | Uso de fator de crescimento de transformação beta e fatores de crescimento anabólico, produto, e, composição farmacêutica | |
| WO1994023722A1 (en) | Hydrocortisone buffering activity | |
| WO2008148572A1 (de) | Antiinflammatorische wirkstoffkombinationen zur behandlung von erkrankungen der haut und schleimhäute | |
| JPH0344048B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE2128462C2 (de) | Arzneimittel auf Basis von Vitamin-A-Säure-Isomeren | |
| EP2723344B1 (de) | Monoterpenhaltiges kombinationstherapeutikum | |
| CH650153A5 (de) | Saponinhaltiges praeparat, das gegen nebennieren-atrophie wirksam ist. | |
| US5478566A (en) | Stimulation of cytokine production | |
| RO120950B1 (ro) | Complex bioactiv de acizi triterpenici, procedeu de obţinere şi produse medicamentoase cu utilizări terapeutice | |
| EP0527241B1 (de) | Verwendung der Ascorbinsäure zur Zubereitung von Arzneimitteln zur Anwendung im Genitalbereich | |
| US10568866B1 (en) | Composition and its use for increasing innate immune health | |
| DE2206570C3 (de) | Verwendung von (+)-Catechin | |
| NZ536360A (en) | Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone | |
| KR890000093A (ko) | 건선의 치료방법 및 치료용 조성물 | |
| EP1275382A2 (de) | Hyperforin als Zytostatikum sowie Hyperforin-Salbe oder -Creme als Applikationsform | |
| EP1212072B1 (de) | Pharmazeutische zusammensetzung, umfassend eukalyptus- und orangenöl | |
| ITMI20070561A1 (it) | Composizioni transdermiche o transmucosali contenenti composti a struttura steroidea | |
| JPH04505160A (ja) | 抗菌剤としてのステロイド化合物の使用 | |
| EP2744504B1 (de) | Verfahren zur herstellung von trockenextrakten | |
| DE102020131716A1 (de) | Neues Therapiekonzept für die Behandlung von Corona-Infektionen, insbesondere COVID-19-Infektionen |